Recent Quotes (30 days)

You have no recent quotes
chg | %

Concordia Healthcare Corp  

(Public, TSE:CXR)   Watch this stock  
Find more results for CXR
+0.76 (2.26%)
Delayed:   1:17PM EDT
TSE data delayed by 15 mins - Disclaimer
Currency in CAD
Range 33.55 - 35.28
52 week 25.04 - 117.75
Open 34.29
Vol / Avg. 969,391.00/949,309.00
Mkt cap 1.77B
P/E     -
Div/yield 0.10/1.12
EPS -1.03
Shares 51.02M
Beta -2.91
Inst. own     -
May 13, 2016
Q1 2016 Concordia Healthcare Corp Earnings Release - 9:30AM EDT - Add to calendar
May 13, 2016
Q1 2016 Concordia Healthcare Corp Earnings Call - 8:30AM EDT - Add to calendar
Apr 29, 2016
Concordia Healthcare Corp Ordinary Shareholders Meeting
Mar 24, 2016
Q4 2015 Concordia Healthcare Corp Earnings Call - Webcast
Mar 23, 2016
Q4 2015 Concordia Healthcare Corp Earnings Release
Feb 24, 2016
Concordia Healthcare Corp at RBC Capital Markets Healthcare Conference

Key stats and ratios

Q4 (Dec '15) 2015
Net profit margin -16.26% -7.46%
Operating margin 1.44% 20.41%
EBITD margin - 54.41%
Return on average assets -3.09% -1.00%
Return on average equity -10.95% -4.16%
Employees 214 -
CDP Score - -


277 Lakeshore Rd E Suite 302
+1-905-8425150 (Phone)
+1-905-8425154 (Fax)

Website links


Concordia Healthcare Corp. is a Canada-based diverse healthcare company. The Company is focused on legacy pharmaceutical products and orphan drugs. The Company operates through three segments, which includes Legacy Pharmaceutical Division, Concordia Pharmaceuticals Inc., which consists of 23 products, including Nilandron, for the treatment of metastatic prostate cancer; Dibenzyline, for the treatment of pheochromocytoma; Lanoxin, for the treatment of mild-to-moderate heart failure and atrial fibrillation; Plaquenil, for the treatment of lupus and rheumatoid arthritis; Donnatal, for the treatment of irritable bowel syndrome, and Zonegran (zonisamide), for treatment of partial seizures in adults with epilepsy. Its Specialty Healthcare Distribution (SHD) Division, Complete Medical Homecare, is engaged in the distribution of medical supplies focused on diabetes and related conditions. Its Orphan Drugs Division, Concordia Laboratories Inc., is engaged in the manufacture of PHOTOFRIN.

Officers and directors

Mark L. Thompson Chairman of the Board, Chief Executive Officer, Founder
Age: 47
Wayne Kreppner President, Chief Operating Officer
Age: 41
Adrian de Saldanha Chief Financial Officer
Robert Altman Ph.D. President - Pinnacle Biologics Inc.
Age: 62
Arijit Mookerjee Managing Director, Chief Financial Officer - Operations
Leith Tessy Treasurer, Secretary
Age: 52
Jordan M. Kupinsky J.D. Lead Independent Director
Age: 42
Patrick Vink M.D. Director
Age: 51
Edward J. Borkowski CPA Independent Director
Age: 55
Douglas N. Deeth Independent Director
Age: 67